Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
Stocktwits on MSN18h
Candel’s Final Survival Data From Lung Cancer Drug Trial Lifts Stock After-Hours, Fuels Retail OptimismCandel Therapeutics Inc. stock ended Wednesday deep in the red but rose 1.3% in extended trading after the company announced ...
Clinical characteristics were associated with different survival outcomes in patients treated with immune checkpoint ...
Candel Therapeutics' CAN-2409 extended survival in NSCLC patients, with biomarker data showing enhanced response in ...
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...
ICI-based combinations are the preferred first-line therapy due to their proven superiority over TKI monotherapy, many patients were not receiving them,” the researchers wrote.
Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.
News Medical on MSN6d
Analysis of new colorectal cancer immunotherapy shows more treatment optionsA team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive ...
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...
Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard ...
EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...
Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback